Pleiotropic effects of cancer cells' secreted factors on human stromal (mesenchymal) stem cells

Stem Cell Research and Therapy

Volumn 4, Issue 5, 2013, Pages

  Al Toub, Mashael ^a   Almusa, Abdulaziz ^a   Almajed, Mohammed ^a   Al Nbaheen, May ^a,b   Kassem, Moustapha ^a,c   Aldahmash, Abdullah ^a,c   Alajez, Nehad M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b SAUDI ELECTRONIC UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ENZYME INHIBITOR; FOCAL ADHESION KINASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PF 573228; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AGILENT MICROARRAY; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL FUNCTION; CELL MIGRATION; CELL STRUCTURE; COLON CANCER; CONTROLLED STUDY; DNA SEQUENCE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG CANCER; MALE; MEDIATOR RELEASE; MESENCHYMAL STROMA CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPISM;

ADIPOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL5; CHEMOKINE CXCL6; CLUSTER ANALYSIS; CULTURE MEDIA, CONDITIONED; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HT29 CELLS; HUMANS; INTERLEUKIN-6; MCF-7 CELLS; MESENCHYMAL STROMAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOGENESIS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

EID: 84883898060     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt325     Document Type: Article

References (50)

1. Minimal criteria for defining multipotent mesenchymal stromal cells, The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
2. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Granero-Molto F, Weis JA, Miga MI, Landis B, Myers TJ, O'Rear L, Longobardi L, Jansen ED, Mortlock DP, Spagnoli A, Stem Cells 2009 27 1887 1898 10.1002/stem.103 19544445
3. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M, J Neurol Sci 2001 189 49 57 10.1016/S0022-510X(01)00557-3 11535233 (Pubitemid 32776649)
4. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Wu GD, Nolta JA, Jin YS, Barr ML, Yu H, Starnes VA, Cramer DV, Transplantation 2003 75 679 685 10.1097/01.TP.0000048488.35010.95 12640309 (Pubitemid 36337368)
5. Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells. Kristensen LP, Chen L, Nielsen MO, Qanie DW, Kratchmarova I, Kassem M, Andersen JS, Mol Cell Proteomics 2012 11 989 1007 10.1074/mcp.M111.012138 22801418
6. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Chamberlain G, Fox J, Ashton B, Middleton J, Stem Cells 2007 25 2739 2749 10.1634/stemcells.2007- 0197 17656645 (Pubitemid 350127858)
7. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Phinney DG, Prockop DJ, Stem Cells 2007 25 2896 2902 10.1634/stemcells.2007-0637 17901396 (Pubitemid 350127874)
8. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE, Circ Res 2004 94 678 685 10.1161/01.RES.0000118601.37875.AC 14739163 (Pubitemid 38387752)
9. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA, Nature 2007 449 557 563 10.1038/nature06188 17914389 (Pubitemid 47525152)
10. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ, Clin Cancer Res 2007 13 5020 5027 10.1158/1078-0432.CCR-07-0731 17785552 (Pubitemid 47502066)
11. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. Dvorak HF, N Engl J Med 1986 315 1650 1659 10.1056/NEJM198612253152606 3537791 (Pubitemid 17052899)
12. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Erez N, Truitt M, Olson P, Arron ST, Hanahan D, Cancer Cell 2010 17 135 147 10.1016/j.ccr.2009.12.041 20138012
13. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, Tsao MS, Proc Natl Acad Sci U S A 2011 108 7160 7165 10.1073/pnas.1014506108 21474781
14. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, Varro A, Tycko B, Wang TC, Cancer Cell 2011 19 257 272 10.1016/j.ccr.2011.01.020 21316604
15. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M, Exp Gerontol 2008 43 1018 1023 10.1016/j.exger.2008.07.004 18694815
16. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T, J Exp Med 2006 203 1235 1247 10.1084/jem.20051921 16636132
17. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF, Cancer Res 2005 65 3307 3318 15833864 (Pubitemid 40524615)
18. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C, Zhao RC, Leukemia 2009 23 925 933 10.1038/leu.2008.384 19148141
19. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Uskokovic MR, Brenner RV, Evans SR, Cancer Res 1994 54 4057 4064 8033137
20. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, Liu FF, Oncotarget 2012 3 1641 1652 23482325
21. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, McCready D, Fyles A, Liu FF, Cancer Res 2011 71 2926 2937 10.1158/0008-5472.CAN-10-3369 21393507
22. Enhanced vesicular stomatitis virus (VSVDelta51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent. Alajez NM, Mocanu JD, Krushel T, Bell JC, Liu FF, Cancer Cell Int 2012 12 27 10.1186/1475-2867-12-27 22704542
23. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Banks-Schlegel SP, Gazdar AF, Harris CC, Cancer Res 1985 45 1187 1197 2578876 (Pubitemid 15111281)
24. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M, Nat Biotechnol 2002 20 592 596 10.1038/nbt0602-592 12042863 (Pubitemid 34595153)
25. Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. Bentzon JF, Stenderup K, Hansen FD, Schroder HD, Abdallah BM, Jensen TG, Kassem M, Biochem Biophys Res Commun 2005 330 633 640 10.1016/j.bbrc.2005.03.072 15809044 (Pubitemid 40462134)
26. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Alajez NM, Shi W, Hui AB, Yue S, Ng R, Lo KW, Bastianutto C, O'Sullivan B, Gullane P, Liu FF, Cell Death Differ 2009 16 1469 1479 10.1038/cdd.2009.85 19575017
27. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Alajez N, Shi W, Hui A, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu F, Cell Death Dis 2010 1 85 10.1038/cddis.2010.64 21368858
28. In vitro differentiation of human skin-derived multipotent stromal cells into putative endothelial-like cells. Vishnubalaji R, Manikandan M, Al-Nbaheen M, Kadalmani B, Aldahmash A, Alajez NM, BMC Dev Biol 2012 12 7 10.1186/1471-213X-12-7 22280443
29. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Grunert S, Jechlinger M, Beug H, Nat Rev Mol Cell Biol 2003 4 657 665 10.1038/nrm1175 12923528 (Pubitemid 36934968)
30. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M, Mol Cancer 2010 9 122 10.1186/1476-4598-9-122 20504320
31. Controlling mesenchymal stem cell differentiation by TGFBeta family members. Roelen BA, Dijke P, J Orthop Sci 2003 8 740 748 10.1007/s00776-003- 0702-2 14557946 (Pubitemid 37288325)
32. Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. Birnbaum T, Hildebrandt J, Nuebling G, Sostak P, Straube A, J Neurooncol 2011 105 57 65 10.1007/s11060-011-0561-1 21547397
33. Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo
34. Immunity, inflammation, and cancer. Grivennikov SI, Greten FR, Karin M, Cell 2010 140 883 899 10.1016/j.cell.2010.01.025 20303878
35. Tumor promotion via injury- and death-induced inflammation. Kuraishy A, Karin M, Grivennikov SI, Immunity 2011 35 467 477 10.1016/j.immuni.2011.09.006 22035839
36. The tumour microenvironment as a target for chemoprevention. Albini A, Sporn MB, Nat Rev Cancer 2007 7 139 147 17218951 (Pubitemid 46160989)
37. A perspective on cancer cell metastasis. Chaffer CL, Weinberg RA, Science 2011 331 1559 1564 10.1126/science.1203543 21436443
38. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS, Cancer Res 2011 71 614 624 10.1158/0008-5472.CAN-10-0538 21224357
39. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M, Cancer Res 2010 70 10044 10050 10.1158/0008-5472.CAN-10-1254 21159629
40. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M, J Natl Cancer Inst 2004 96 1593 1603 10.1093/jnci/djh299 15523088 (Pubitemid 39534883)
41. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe MF, Janes SM, Cancer Res 2009 69 8862 8867 10.1158/0008-5472.CAN-09-1912 19920196
42. Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L, J Ovarian Res 2010 3 12 10.1186/1757-2215-3-12 20500878
43. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C, Blood 2003 102 3837 3844 10.1182/blood-2003-04-1193 12881305 (Pubitemid 37409409)
44. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Brune JC, Tormin A, Johansson MC, Rissler P, Brosjo O, Lofvenberg R, von Steyern FV, Mertens F, Rydholm A, Scheding S, Int J Cancer 2011 129 319 330 10.1002/ijc.25697 20878957
45. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, Lin RJ, Yang DM, Chang CW, Chen WH, Wei HJ, Gelovani JG, Clin Cancer Res 2005 11 7749 7756 10.1158/1078-0432.CCR-05-0876 16278396 (Pubitemid 41611618)
46. Differential mechanical response of mesenchymal stem cells and fibroblasts to tumor-secreted soluble factors. McGrail DJ, Ghosh D, Quach ND, Dawson MR, PLoS One 2012 7 33248 10.1371/journal.pone.0033248 22438903
47. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J, Cell 2012 150 165 178 10.1016/j.cell.2012.04.042 22770218
48. CXCL2 synthesized by oral squamous cell carcinoma is involved in cancer-associated bone destruction. Oue E, Lee JW, Sakamoto K, Iimura T, Aoki K, Kayamori K, Michi Y, Yamashiro M, Harada K, Amagasa T, Yamaguchi A, Biochem Biophys Res Commun 2012 424 456 461 10.1016/j.bbrc.2012.06.132 22771802
49. Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. Burns JS, Kristiansen M, Kristensen LP, Larsen KH, Nielsen MO, Christiansen H, Nehlin J, Andersen JS, Kassem M, PLoS One 2011 6 21888 10.1371/journal.pone. 0021888 21779348
50. Therapeutic targeting of VEGF in the treatment of glioblastoma. Robles Irizarry L, Hambardzumyan D, Nakano I, Gladson CL, Ahluwalia MS, Expert Opin Ther Targets 2012 16 973 984 10.1517/14728222.2012.711817 22876981